PIPELINE
Severe Infections
CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development for the treatment of severe community-acquired bacterial pneumonia (SCAP).
Acquired immune deficiency
Groundbreaking approach tailored to treat acquired immune deficiency in critically ill patients by restoring immune function and immune homeostasis.
NEWS
Combioxin announces non-dilutive funding from the Swiss Innovation Agency (Innosuisse) for its novel drug to treat acquired immune deficiency in critically ill patients
June 11, 2026
FDA grants Qualified Infectious Disease Product (QIDP) and Fast-Track Designations for CAL02
June 13, 2023
FOUNDING TEAM
Samareh Azeredo da Silveira Lajaunias, PhD
Managing Director
Frédéric Lajaunias, PhD
Managing Director
CONTACT US
Address
Route de la Corniche 8
1066 Epalinges – Switzerland
info(a7)combioxin.com